KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Bristol Myers Squibb (BMY) over the last 16 years, with Q4 2025 value amounting to $584.0 million.

  • Bristol Myers Squibb's Asset Writedowns and Impairment fell 7009.73% to $584.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.9 billion, marking a year-over-year decrease of 307.12%. This contributed to the annual value of $1.1 billion for FY2025, which is 6294.3% down from last year.
  • Bristol Myers Squibb's Asset Writedowns and Impairment amounted to $584.0 million in Q4 2025, which was down 7009.73% from $196.0 million recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Asset Writedowns and Impairment ranged from a high of $2.0 billion in Q4 2024 and a low of $1.0 million during Q1 2024
  • Moreover, its 5-year median value for Asset Writedowns and Impairment was $100.0 million (2022), whereas its average is $299.1 million.
  • As far as peak fluctuations go, Bristol Myers Squibb's Asset Writedowns and Impairment tumbled by 9860.07% in 2021, and later soared by 663448.28% in 2024.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's Asset Writedowns and Impairment stood at $15.0 million in 2021, then surged by 133.33% to $35.0 million in 2022, then dropped by 17.14% to $29.0 million in 2023, then skyrocketed by 6634.48% to $2.0 billion in 2024, then plummeted by 70.1% to $584.0 million in 2025.
  • Its last three reported values are $584.0 million in Q4 2025, $196.0 million for Q3 2025, and $2.0 billion during Q4 2024.